Osteocalcin effect on human β-cells mass and function

Omaima M. Sabek, Satoru Nishimoto, Daniel Fraga, Neelam Tejpal, Camillo Ricordi, A. O. Gaber

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The osteoblast-specific hormone osteocalcin (OC) was found to regulate glucose metabolism, fat mass, and β-cell proliferation in mice. Here, we investigate the effect of decarboxylated OC (D-OC) on human β-cell function and mass in culture and in vivo using a Nonobese diabetic-severe combined immunodeficiency mouse model. We found that D-OC at dose ranges from 1.0 to 15 ng/mL significantly augmented insulin content and enhanced human β-cell proliferation of cultured human islets. This was paralleled by increased expression of sulfonylurea receptor protein; a marker of β-cell differentiation and a component of the insulin-secretory apparatus. Moreover, in a Nonobese diabetic-severe combined immunodeficiency mouse model, systemic administration of D-OC at 4.5-ng/h significantly augmented production of human insulin and C-peptide from the grafted human islets. Finally, histological staining of the human islet grafts showed that the improvement in the β-cell function was attributable to an increase in β-cell mass as a result of β-cell proliferation indicated by MKI67 staining together with the increased β-cell number and decreased α-cell number data obtained using laser scanning cytometry. Our data for the first time show D-OC-enhanced β-cell function in human islets and support future exploitation of D-OC-mediated β-cell regulation for developing useful clinical treatments for patients with diabetes.

Original languageEnglish (US)
Pages (from-to)3137-3146
Number of pages10
JournalEndocrinology
Volume156
Issue number9
DOIs
StatePublished - Jan 1 2015

Fingerprint

Osteocalcin
Severe Combined Immunodeficiency
Cell Proliferation
Insulin
Laser Scanning Cytometry
Cell Count
Sulfonylurea Receptors
Staining and Labeling
Secretory Component
C-Peptide
Osteoblasts
Adipocytes
Cell Differentiation
Hormones
Transplants
Glucose
Proteins

All Science Journal Classification (ASJC) codes

  • Endocrinology

Cite this

Sabek, O. M., Nishimoto, S., Fraga, D., Tejpal, N., Ricordi, C., & Gaber, A. O. (2015). Osteocalcin effect on human β-cells mass and function. Endocrinology, 156(9), 3137-3146. https://doi.org/10.1210/EN.2015-1143

Osteocalcin effect on human β-cells mass and function. / Sabek, Omaima M.; Nishimoto, Satoru; Fraga, Daniel; Tejpal, Neelam; Ricordi, Camillo; Gaber, A. O.

In: Endocrinology, Vol. 156, No. 9, 01.01.2015, p. 3137-3146.

Research output: Contribution to journalArticle

Sabek, OM, Nishimoto, S, Fraga, D, Tejpal, N, Ricordi, C & Gaber, AO 2015, 'Osteocalcin effect on human β-cells mass and function', Endocrinology, vol. 156, no. 9, pp. 3137-3146. https://doi.org/10.1210/EN.2015-1143
Sabek OM, Nishimoto S, Fraga D, Tejpal N, Ricordi C, Gaber AO. Osteocalcin effect on human β-cells mass and function. Endocrinology. 2015 Jan 1;156(9):3137-3146. https://doi.org/10.1210/EN.2015-1143
Sabek, Omaima M. ; Nishimoto, Satoru ; Fraga, Daniel ; Tejpal, Neelam ; Ricordi, Camillo ; Gaber, A. O. / Osteocalcin effect on human β-cells mass and function. In: Endocrinology. 2015 ; Vol. 156, No. 9. pp. 3137-3146.
@article{b450da9e73374fd6a34f1808609736b5,
title = "Osteocalcin effect on human β-cells mass and function",
abstract = "The osteoblast-specific hormone osteocalcin (OC) was found to regulate glucose metabolism, fat mass, and β-cell proliferation in mice. Here, we investigate the effect of decarboxylated OC (D-OC) on human β-cell function and mass in culture and in vivo using a Nonobese diabetic-severe combined immunodeficiency mouse model. We found that D-OC at dose ranges from 1.0 to 15 ng/mL significantly augmented insulin content and enhanced human β-cell proliferation of cultured human islets. This was paralleled by increased expression of sulfonylurea receptor protein; a marker of β-cell differentiation and a component of the insulin-secretory apparatus. Moreover, in a Nonobese diabetic-severe combined immunodeficiency mouse model, systemic administration of D-OC at 4.5-ng/h significantly augmented production of human insulin and C-peptide from the grafted human islets. Finally, histological staining of the human islet grafts showed that the improvement in the β-cell function was attributable to an increase in β-cell mass as a result of β-cell proliferation indicated by MKI67 staining together with the increased β-cell number and decreased α-cell number data obtained using laser scanning cytometry. Our data for the first time show D-OC-enhanced β-cell function in human islets and support future exploitation of D-OC-mediated β-cell regulation for developing useful clinical treatments for patients with diabetes.",
author = "Sabek, {Omaima M.} and Satoru Nishimoto and Daniel Fraga and Neelam Tejpal and Camillo Ricordi and Gaber, {A. O.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1210/EN.2015-1143",
language = "English (US)",
volume = "156",
pages = "3137--3146",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "9",

}

TY - JOUR

T1 - Osteocalcin effect on human β-cells mass and function

AU - Sabek, Omaima M.

AU - Nishimoto, Satoru

AU - Fraga, Daniel

AU - Tejpal, Neelam

AU - Ricordi, Camillo

AU - Gaber, A. O.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The osteoblast-specific hormone osteocalcin (OC) was found to regulate glucose metabolism, fat mass, and β-cell proliferation in mice. Here, we investigate the effect of decarboxylated OC (D-OC) on human β-cell function and mass in culture and in vivo using a Nonobese diabetic-severe combined immunodeficiency mouse model. We found that D-OC at dose ranges from 1.0 to 15 ng/mL significantly augmented insulin content and enhanced human β-cell proliferation of cultured human islets. This was paralleled by increased expression of sulfonylurea receptor protein; a marker of β-cell differentiation and a component of the insulin-secretory apparatus. Moreover, in a Nonobese diabetic-severe combined immunodeficiency mouse model, systemic administration of D-OC at 4.5-ng/h significantly augmented production of human insulin and C-peptide from the grafted human islets. Finally, histological staining of the human islet grafts showed that the improvement in the β-cell function was attributable to an increase in β-cell mass as a result of β-cell proliferation indicated by MKI67 staining together with the increased β-cell number and decreased α-cell number data obtained using laser scanning cytometry. Our data for the first time show D-OC-enhanced β-cell function in human islets and support future exploitation of D-OC-mediated β-cell regulation for developing useful clinical treatments for patients with diabetes.

AB - The osteoblast-specific hormone osteocalcin (OC) was found to regulate glucose metabolism, fat mass, and β-cell proliferation in mice. Here, we investigate the effect of decarboxylated OC (D-OC) on human β-cell function and mass in culture and in vivo using a Nonobese diabetic-severe combined immunodeficiency mouse model. We found that D-OC at dose ranges from 1.0 to 15 ng/mL significantly augmented insulin content and enhanced human β-cell proliferation of cultured human islets. This was paralleled by increased expression of sulfonylurea receptor protein; a marker of β-cell differentiation and a component of the insulin-secretory apparatus. Moreover, in a Nonobese diabetic-severe combined immunodeficiency mouse model, systemic administration of D-OC at 4.5-ng/h significantly augmented production of human insulin and C-peptide from the grafted human islets. Finally, histological staining of the human islet grafts showed that the improvement in the β-cell function was attributable to an increase in β-cell mass as a result of β-cell proliferation indicated by MKI67 staining together with the increased β-cell number and decreased α-cell number data obtained using laser scanning cytometry. Our data for the first time show D-OC-enhanced β-cell function in human islets and support future exploitation of D-OC-mediated β-cell regulation for developing useful clinical treatments for patients with diabetes.

UR - http://www.scopus.com/inward/record.url?scp=84942801795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942801795&partnerID=8YFLogxK

U2 - 10.1210/EN.2015-1143

DO - 10.1210/EN.2015-1143

M3 - Article

VL - 156

SP - 3137

EP - 3146

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 9

ER -